Sarepta Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021
November 04, 2021 at 01:34 am IST
Share
Sarepta Therapeutics, Inc. reported earnings results for the third quarter and nine months ended September 30, 2021. For the third quarter, the company reported revenue was USD 189.41 million compared to USD 143.92 million a year ago. Net loss was USD 48.14 million compared to USD 196.5 million a year ago. Basic loss per share from continuing operations was USD 0.6 compared to USD 2.5 a year ago. Diluted loss per share from continuing operations was USD 0.6 compared to USD 2.5 a year ago.
For the nine months, revenue was USD 500.43 million compared to USD 394.96 million a year ago. Net loss was USD 296.8 million compared to USD 364.81 million a year ago. Basic loss per share from continuing operations was USD 3.72 compared to USD 4.7 a year ago. Diluted loss per share from continuing operations was USD 3.72 compared to USD 4.7 a year ago.
Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on helping patients through the discovery and development of ribonucleic acid (RNA)-targeted therapeutics, gene therapy and other genetic therapeutic modalities for the treatment of rare diseases. It has developed multiple approved products for the treatment of Duchenne muscular dystrophy (Duchenne) and is developing potential therapeutic candidates for a range of diseases and disorders, including Duchenne, Limb-girdle muscular dystrophies (LGMDs) and other neuromuscular and central nervous system (CNS) related disorders. It has developed and commercialized four approved products for the treatment of Duchenne: EXONDYS 51 (eteplirsen), Injection (EXONDYS 51), VYONDYS 53 (golodirsen) Injection (VYONDYS 53), AMONDYS 45 (casimersen) Injection (AMONDYS 45), and ELEVIDYS. Its pipeline includes approximately 40 programs at various stages of discovery, pre-clinical and clinical development.